Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis

INTRODUCTION: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) is the first direct-acting antiviral (DAA) therapy approved for patients who have previously failed a DAA-containing regimen including NS5A inhibitors. In clinical trials, SOF/VEL/VOX was associated with high rates of sustained virologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jing, Xu, Bin, Wei, Linlin, Huang, Chunyang, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334482/
https://www.ncbi.nlm.nih.gov/pubmed/35749010
http://dx.doi.org/10.1007/s40121-022-00666-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334482/
https://www.ncbi.nlm.nih.gov/pubmed/35749010
http://dx.doi.org/10.1007/s40121-022-00666-0

Ejemplares similares